Cover Image

PAPERBACK
$43.50



View/Hide Left Panel

TABLE 9.1 Health Benefits and Expenditures Associated with Various Vaccine Candidates: Central Analysis

Pathogen (Target Population)

Vaccine Envisaged

Annualized Present Value of Potential Health Benefits (IME Units)

Annualized Present Value of Expenditures on Vaccines Necessary to Achieve Potential Health Benefits ($ millions)

Dengue virus

(Infants and children in endemic areas; travelers to endemic areas)

Attenuated live vector virus containing gene for broadly cross-reacting protective antigen

9,558

242

Escherichia coli

(enterotoxigenic)

(Infants < 6 months)

A combination of purified colonization factor antigens and possibly other antigens

126,454

722

Genetically engineered attenuated strains

145,260

69

Hemophilus influenzae type b

(Infants)

Conjugated polysaccharide

210,943

527

Hepatitis A virus

(Susceptibles of all ages; routine for preschool children)

Attenuated live virus

15,112

1,058

Polypeptide recombinant vaccine produced in yeast

14,392

4,029

Hepatitis B virus

(Areas with high perinatal infection: all infants at birth (if possible). Other areas: all infants, simultaneous with other vaccinations)

Polypeptide produced by recombinant DNA technology

213,192

8,859

Japanese encephalitis virus

(Children in epidemic and and endemic areas; foreign visitors to epidemic regions)

Inactivated virus produced in cell culture

3,232

614



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement